Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF)

Viviani, Laura; Harrison, Michael J.; Zolin, A.; Haworth, Charles; Floto, Andres

doi:10.1016/j.jcf.2016.03.002

Cited by 53 publications

(60 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While supported by epidemiological findings from a previous case–control in Israel43 and a recent European CF Society Patient Registry study,89 other large retrospective studies have shown no such association, potentially highlighting the complex relationship between the antibiotic and immunomodulatory properties of azithromycin during NTM infection 90–95…”

Section: Section 3: Epidemiology Of Ntm-pulmonary Diseasementioning

confidence: 89%

British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

Haworth

Banks

Capstick

et al. 2017

Thorax

595

679

View full text Add to dashboard Cite

Section: Section 3: Epidemiology Of Ntm-pulmonary Diseasementioning

confidence: 89%

British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

Haworth

Banks

Capstick

et al. 2017

Thorax

595

679

View full text Add to dashboard Cite

“…Interestingly, P. aeruginosa and H. influenzae have been described to competitively inhibit each other, which in turn alters the core microbiota in the non-CF bronchiectasis airway [28]. Non-tuberculous mycobacteria (NTM) form another significant group of pathogens colonizing CF and non-CF airways [29][30][31]. Mycobacterium avium complex (MAC) and Mycobacterium abscessus are most frequently isolated in CF [32,33] with high rates of multi-drug resistance in these species making them notoriously difficult to treat [34].…”

Section: Microbiologymentioning

confidence: 99%

Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis

Schäfer

Griese²,

Chandrasekaran

et al. 2018

BMC Pulm Med

View full text Add to dashboard Cite

Bronchiectasis is a common feature of severe inherited and acquired pulmonary disease conditions. Among inherited diseases, cystic fibrosis (CF) is the major disorder associated with bronchiectasis, while acquired conditions frequently featuring bronchiectasis include post-infective bronchiectasis and chronic obstructive pulmonary disease (COPD). Mechanistically, bronchiectasis is driven by a complex interplay of inflammation and infection with neutrophilic inflammation playing a predominant role. The clinical characterization and management of bronchiectasis should involve a precise diagnostic workup, tailored therapeutic strategies and pulmonary imaging that has become an essential tool for the diagnosis and follow-up of bronchiectasis. Prospective future studies are required to optimize the diagnostic and therapeutic management of bronchiectasis, particularly in heterogeneous non-CF bronchiectasis populations.

show abstract

“…Prevalence rates of MABSC vary between CF centers and regions studied for reasons that are not well‐understood, although this is also the case with other CF pathogens like Pseudomonas aeruginosa, Burkholderia cepacia complex, and Achromobacter xylosoxidans . There are, however, strong ascertainment biases involved in the mycobacterial diagnostic process, which are likely to contribute significantly to variations in reported incidence rates.…”

Section: Why Early Diagnosis Is Importantmentioning

confidence: 99%

The importance of early diagnosis of Mycobacterium abscessus complex in patients with cystic fibrosis

Ravnholt

Kolpen

Skov

et al. 2018

APMIS

View full text Add to dashboard Cite

Mycobacterium abscessus complex can cause severe lung infections and has proven to be a serious threat to patients with cystic fibrosis and a challenge for clinicians due to difficulties in timely diagnosis and complex multidrug treatment regimes. Mycobacterial culture is the gold standard for diagnosis, but in most cystic fibrosis centers it is performed less frequently than culture for other pathogens. Consensus today recommends just one annual mycobacterial culture for asymptomatic patients with cystic fibrosis, a strategy likely to lead to diagnostic delays. Postponement of diagnosis might be the deciding factor in whether an early colonization turns into chronic infection. This review highlights the latest developments in knowledge about the pathogenicity and clinical consequences of M. abscessus complex pulmonary disease, addressing the central theme of why pulmonary infection requires early identification and aggressive antibiotic treatment. The window of opportunity, before M. abscessus complex transforms from a mucosal colonizer to a chronic biofilm infection, is where microbial eradication is most likely to be successful, making early diagnosis essential for improved outcomes.

show abstract

Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF)

Cited by 53 publications

References 19 publications

British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis

The importance of early diagnosis of Mycobacterium abscessus complex in patients with cystic fibrosis

Contact Info

Product

Resources

About